Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Summary

The purpose of this phase I study is to evaluate the safety and efficacy of pembrolizumab in combination with Lenvatinib in patients with pancreatic ductal adenocarcinoma.

General Information

NCT#: NCT05273554
Study ID: 2021-0274
Trial Phase: Phase I

Trial Sponsor: M.D. Anderson Cancer Center
Therapies Used in This Trial: Pembrolizumab, Lenvatinib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search